This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

This study has been completed.
Information provided by:
BeerYaakov Mental Health Center Identifier:
First received: April 16, 2008
Last updated: June 15, 2008
Last verified: June 2008
Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.

Condition Intervention Phase
Schizophrenia Drug: Placebo Drug: Trazodone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by BeerYaakov Mental Health Center:

Primary Outcome Measures:
  • Barnes Akathisia rating scale, Positive and Negative syndrome scale, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms

Enrollment: 13
Study Start Date: November 2000
Study Completion Date: December 2003
Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
The patients in this arm received placebo
Drug: Placebo
Active Comparator: Trazodone
The patients on this arm received Trazodone for 3 consecutive days
Drug: Trazodone


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with akathisia according to DSM-IV criteria at least mild akathisia.

Exclusion Criteria:

  • Change of pharmacologic regimen 7 days prior to study entry
  • Significant systemic disease
  • The presence of chronic akathisia
  • Patients unable to cooperate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00659919

Beer Yaakov MHC
Beer Yaacov, Israel, 70350
Sponsors and Collaborators
BeerYaakov Mental Health Center
  More Information Identifier: NCT00659919     History of Changes
Other Study ID Numbers: Trazodone-60CTIL
Study First Received: April 16, 2008
Last Updated: June 15, 2008

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents processed this record on August 17, 2017